Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Renalytix Plc is a clinical diagnostics company focused on improving the early detection and management of kidney disease through advanced biomarker analysis and artificial intelligence–driven risk assessment. The company operates within the in vitro diagnostics, clinical laboratory testing, and healthcare analytics industries, with a primary emphasis on chronic kidney disease (CKD) and diabetic kidney disease. Its core commercial offering is KidneyIntelX, a laboratory-developed test that combines blood-based biomarkers with clinical data and machine learning algorithms to assess the risk of progressive kidney function decline.
Founded in 2014, Renalytix evolved from academic research and clinical collaboration in nephrology into a publicly listed diagnostics developer. The company has positioned itself as a precision medicine provider in nephrology, aiming to address unmet needs in early risk stratification where traditional clinical measures have limited predictive accuracy. Renalytix has pursued regulatory, reimbursement, and clinical adoption pathways primarily in the United States, while maintaining strong ties to academic and healthcare institutions in the United Kingdom.
Business Operations
Renalytix operates as a single-reportable business centered on kidney disease diagnostics, generating revenue primarily from clinical testing services, research collaborations, and limited commercial deployments. Its flagship product, KidneyIntelX, is performed through certified clinical laboratory infrastructure and is designed for use by healthcare providers managing patients with type 2 diabetes and early-stage CKD. Revenue generation has historically been constrained by regulatory review timelines and reimbursement coverage decisions, particularly in the U.S. Medicare system.
Operationally, the company conducts activities across the U.S. and U.K., leveraging proprietary algorithms, licensed biomarker technologies, and validated clinical datasets. Renalytix conducts testing through its U.S.-based laboratory operations and maintains intellectual property related to biomarker combinations and risk prediction models. The company also engages in partnerships with health systems, academic institutions, and biopharmaceutical companies to support clinical validation and potential companion diagnostic applications.
Strategic Position & Investments
Renalytix’s strategy centers on establishing KidneyIntelX as a clinically adopted and reimbursed standard-of-care test for early kidney disease risk assessment. Growth initiatives have included pursuing U.S. Food and Drug Administration review pathways, obtaining Breakthrough Device Designation, and conducting large-scale clinical validation studies. The company has also focused on generating real-world evidence to support payer adoption and integration into population health management programs.
The company’s investment activities have primarily targeted internal research and development rather than large-scale acquisitions. Its notable operating subsidiary, RenalytixAI, Inc., supports U.S. commercial and laboratory operations. Renalytix has indicated interest in expanding its technology platform to additional kidney-related indications and adjacent cardio-metabolic conditions, though data on commercial expansion beyond KidneyIntelX remains limited based on available public disclosures.
Geographic Footprint
Renalytix maintains a transatlantic operational footprint, with corporate and research roots in the United Kingdom and primary commercial focus in the United States. The company is headquartered in Cardiff, Wales, and maintains significant operational presence in New York and other U.S. healthcare markets to support laboratory services, regulatory engagement, and commercial partnerships.
Its market presence is concentrated in North America and Europe, with the U.S. representing the largest target market due to the prevalence of diabetic kidney disease and the scale of the Medicare system. While Renalytix has engaged in international research collaborations, there is limited evidence of material revenue generation outside these core regions based on publicly available filings and disclosures.
Leadership & Governance
Renalytix is led by an executive team with experience in diagnostics, biotechnology commercialization, and clinical nephrology. The leadership emphasizes evidence-based medicine, regulatory rigor, and integration of artificial intelligence into routine clinical workflows as core elements of its strategic vision.
Key executives include:
- James McCullough – Chief Executive Officer
- Paul G. Kennedy – Chief Financial Officer
- Jonathan Barratt – Chief Medical Officer
The company’s governance structure includes a board with clinical, financial, and life sciences expertise, reflecting its focus on navigating regulatory pathways and achieving clinical adoption. Some details regarding historical role changes and board composition show variation across public disclosures; where discrepancies exist, data is inconclusive based on available public sources.